Andrew Sargeant

Andrew Sargeant serves as a key procurement professional within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, supporting the agency’s mission to accelerate the acquisition and deployment of medical countermeasures for public health emergencies. He manages complex research and development contracts focused on biodefense preparedness, specializing in the procurement of advanced therapeutics, vaccines, and diagnostic platforms. His work directly enables the rapid scaling of innovative biomedical solutions against emerging infectious threats, bioterrorism agents, and pandemic-level hazards, aligning acquisition strategy with national health security priorities. Sargeant maintains consistent contracting relationships with specialized biotechnology firms including Cidara Therapeutics, Aquestive Therapeutics, Rafa Laboratories, and Osivax, all of which possess niche capabilities in antiviral drug development, novel drug delivery systems, and pandemic-ready vaccine platforms. His procurement approach emphasizes partnerships with firms possessing proven expertise in GMP manufacturing, preclinical validation, and clinical-stage product development, fostering long-term collaborations grounded in technical rigor and regulatory compliance. These vendor relationships are strategically cultivated to ensure agility in responding to urgent public health needs. Sargeant’s contracting portfolio reflects a uniform preference for full and open competition, with 100% of awards issued without set-asides for 8(a), HUBZone, SDVOSB, or other socioeconomic programs. This reflects a mission-driven focus on speed and technical capability over socioeconomic targeting, prioritizing the most qualified entities capable of delivering critical medical countermeasures under accelerated timelines. His primary procurement activity centers on NAICS 541714—Research and Development in Biotechnology—where he sources advanced biologics, antiviral compounds, mRNA platforms, and novel adjuvant systems. His technical expertise lies in the acquisition of preclinical and clinical-stage biopharmaceutical innovations, ensuring the federal government’s access to cutting-edge biodefense technologies through strategic, science-based contracting.